SCHEMBL10275449

SCHEMBL10275449

O=c1c2ccc(N3CCOCC3)cc2nc(S)n1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 1/20 0.54
▸ IDO2 Q6ZQW0 1/20 0.54
▸ PIK3CD O00329 1/20 0.47
▸ PIK3CA P42336 1/20 0.47
▸ PIK3CB P42338 1/20 0.47
▸ MAT2A P31153 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ ALDH1A1 P00352 6/20 0.45
▸ USP2 O75604 3/20 0.45
▸ CYP1A2 P05177 3/20 0.45
▸ CASP1 P29466 3/20 0.45
▸ CASP7 P55210 3/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ HPGD P15428 3/20 0.45
▸ MAPK1 P28482 3/20 0.45
▸ HIF1A Q16665 2/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ PRKDC P78527 2/20 0.45
▸ TSHR P16473 2/20 0.44
▸ MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9670555 0.76 NPC1 (0.58) SMN1; SMN2ALDH1A1HSD17B10HPGDMAPK1
SCHEMBL9671236 0.76 SMN1; SMN2 (0.50) TDO2IDO2MAT2ASMN1; SMN2ALDH1A1
SCHEMBL4957015 0.74 MAPT (0.62) TDO2IDO2SMN1; SMN2ALDH1A1HPGD
SCHEMBL12788438 0.73 TDO2 (0.47) TDO2IDO2PIK3CDPIK3CAPIK3CB
SCHEMBL5028783 0.70 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4593804 0.70 TDO2 (0.62) TDO2IDO2PIK3CDPIK3CAPIK3CB
SCHEMBL17830820 0.70 TDO2 (0.69) TDO2IDO2MEN1KMT2AHSP90AA1
SCHEMBL24384617 0.69 PRKDC (0.52) PIK3CDPIK3CAPIK3CBSMN1; SMN2ALDH1A1
SCHEMBL9670140 0.69 MEN1 (0.51) TDO2IDO2SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL9671456 0.69 KDM4E (0.51) TDO2IDO2MAT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 — — US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 — — US disclosed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 — — US disclosed
WO-2011035518-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF 辽宁利锋科技开发有限公司 (CN) 2011-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 TDO2 336/4885IDO2 1507/4885PIK3CD 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback